Shares in pharmaceutical company Elan jumped by more than 8% in Dublin today after it and its partner Biogen said trial results from their Antegren treatment for multiple sclerosis had been positive.
The companies said a study of 942 patients showed that Antegren reduced the rate of relapses by 66%.
Elan and Biogen have submitted applications for the approval of Antegren as an MS treatment in the US, EU, Canada and Australia. The results released today are from one year of trials. Two-year figures will be available in the first half of 2005.
Shares in the company closed over 8% higher in Dublin this evening at €23.08 in Dublin - a gain of €1.73.
